Navigation Links
NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
Date:9/26/2011

TOKYO, September 27, 2011 /PRNewswire/ --

NVA237 has been filed for marketing authorisation by Novartis with the European Medicines Agency (EMA) under the brand-name Seebri® Breezhaler®, triggering a $5m milestone payment to Sosei

Studies show investigational once-daily NVA237 provides superior 24-hour bronchodilation and increases exercise endurance relative to placebo

Additional data show NVA237 significantly prolonged time to first moderate/ severe COPD exacerbation and reduced associated hospitalizations compared to placebo

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), today announces that NVA237 (glycopyrronium bromide), a long-acting muscarinic antagonist (LAMA) being investigated as a once-daily treatment for chronic obstructive pulmonary disease (COPD), has been filed by Novartis for marketing authorisation with the European Medicines Agency (EMA), under the brand-name Seebri® Breezhaler®, triggering a $5m milestone payment to Sosei.

In addition, Novartis has presented new NVA237 Phase III data at the European Respiratory Society (ERS) congress.  The GLOW1 and GLOW3 studies in chronic obstructive pulmonary disease (COPD) patients show that NVA237 (glycopyrronium bromide) significantly increased patients' lung function compared to placebo with a fast onset of action at first dose, as well as improving exercise endurance.  NVA237 is a new drug in the long-acting anti-muscarinic (LAMA) class.

The GLOW1 study met its primary endpoint by showing that NVA237 50 mcg once-daily produced a significant improvement in lung function of 108 mL in trough FEV1 (forced expiratory volume of breath in one second) after 12 weeks in patients with moderate-to-severe COPD compared to placebo (p<0.001). Moreover, NVA237 had a rapid onset of action, with a 93 mL improvement in FEV1 compared to placebo at five minutes post-dose fo
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
2. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
3. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
4. 13D Amendment Filed for RepliGen Corporation
5. Mr. Ronald L. Chez Filed Amended 13D for RepliGen Corporation
6. Recalled DePuy ASR Hip Implant Lawsuits Filed By John David Hart
7. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
8. Recalled DePuy Hip Implant Lawsuits Filed in Fort Worth, Texas
9. Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
10. Law Offices of John David Hart: DePuy Recalled Hip Device Lawsuit Filed by Houston Woman
11. DePuy Recalled Hip Device Lawsuit Filed in Austin, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  ALPHAEON ... lifestyle healthcare and subsidiary of Strathspey ... acquired Physician Recommended Nutriceuticals (PRN) ® , a ... related products for dry eye and ... a transaction worth up to $55M. ...
(Date:7/28/2014)... 28, 2014 Concord Medical Services Holdings Limited ... ), a leading specialty hospital management solution provider and ... imaging centers in China , today ... Directors declared a special cash dividend of US$0.30 per ... on the Company,s outstanding ordinary shares. The total expense ...
(Date:7/28/2014)... TOKYO , July 28, 2014 /PRNewswire/ ... appointed Roger Crystal , MD as Vice President ... the Global Business Development Product Acquisition & Licensing team ... in developing business strategy and partnerships in the precision ... to partner with biotechnology and pharmaceutical companies across the ...
Breaking Medicine Technology:ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3Concord Medical Declares Special Dividend 2ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2
... 14, 2011 Life Technologies Corporation ... delivery technology specially designed for therapeutic applications that is ... available for licensing as part of a new out-licensing ... the novel proprietary siRNA delivery reagents by using new ...
... Imaging has achieved proof-of-concept with the first fully automated ... CT angiography (cCTA) study. This technology, the first to ... the potential to eliminate the need for a separate ... decrease patient radiation exposure. This work in progress is ...
Cached Medicine Technology:Life Technologies Develops Potent Drug Delivery Technology for Therapeutics Market 2Life Technologies Develops Potent Drug Delivery Technology for Therapeutics Market 3Rcadia's Fully Automatic Calcium Score Assessment from Coronary CTA Shows Potential to Eliminate Need for Separate Scan 2
(Date:7/29/2014)... 2014 Current Back2Basics long-term drug rehab ... post foot surgery during his first six months of sobriety. ... – twice on one foot, once on the other– which ... my foot a year ago and was prescribed drugs that ... by a friend from home who’d recently completed the program. ...
(Date:7/29/2014)... 29, 2014 Couples rule at Maui's only ... Wailea. This September through November, the focus is on ... to couples of all ages and interests. Best of ... advantage of the Resort's popular Experience More package , ... yearly sale" is in full swing in the award-winning restaurants, ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The Multiple ... organization has announced the appointment of five new members ... the Coalition announced the election of its executive directors. ... 6 Board members and 2 Physician Advisors. These ... MSA Coalition mission of education, support, advocacy and research ...
(Date:7/29/2014)... 2014 Septic tanks have ... This score reflects a buyer's moderate ability to negotiate ... of suppliers, the product's widespread availability and the price-competitive ... Jordan Weinstein. IBISWorld estimates that there are more than ... of supplier options. However, recent demand growth and rising ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Ticketability.com has reduced ... have already been selling at lower prices on the secure ... receive a further discount on tickets that are priced lower ... selection of tickets available at Ticketability.com. , Theatergoers know that ... eager to find Phantom of the Opera tickets for sale ...
Breaking Medicine News(10 mins):Health News:Back2Basics Sober Living Resident Overcomes Obstacle in Early Sobriety 2Health News:Four Seasons Resort Maui at Wailea Goes All Out to Give Couples Memorable Get-Away this Fall at Maui’s Luxury Resort 2Health News:Four Seasons Resort Maui at Wailea Goes All Out to Give Couples Memorable Get-Away this Fall at Maui’s Luxury Resort 3Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 2Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 3Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 4Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 4Health News:Phantom of the Opera Tickets for Sale: Ticketability.com Delights Customers with Phantom of the Opera Theatre Tickets While Seats Last 2
... mouse genetic system co-developed by researchers at the University of ... biologist Hui Zong has isolated the cellular origin for malignant ... oligodendrocyte precursor cells (OPCs) are the point of origin is ... the July 22 issue of the journal Cell . ...
... , THURSDAY, July 7 (HealthDay News) -- The female ancestor ... lived in the vicinity of present-day Britain and Ireland 20,000 ... scientists. It,s likely that climate changes that affected the ... habitats and interbreeding between brown bears and polar bears. This ...
... Identifying a suitable donor for leukemia and lymphoma patients ... now that results of two clinical trials show transplant ... are comparable to fully matched tissue, thanks in large ... special post-transplant chemotherapy. The finding means that nearly ...
... Family doctors are reluctant to disclose identifiable patient ... mostly in an effort to protect patient privacy. A ... Canada Research Chair in Electronic Health Information at the ... Ontario Research Institute recently found that during the peak ...
... Gender may be associated with an increased risk ... knees, according to research being presented at the American ... Diego. "Having articular cartilage lesions ... the knee) is considered a predictor of future osteoarthritis-a ...
... In the largest reported series yet to compare transcervical ... staging and restaging of non-small cell lung cancer (NSCLC), ... research presented at the 14th World Conference on Lung ... the Study of Lung Cancer (IASLC). Diagnostic yield ...
Cached Medicine News:Health News:Cellular origin of deadly brain cancer is identified 2Health News:Cellular origin of deadly brain cancer is identified 3Health News:Female Ancestor of All Living Polar Bears Was Brown 2Health News:Half-matched transplants widen pool of donors for leukemia and lymphoma 2Health News:Half-matched transplants widen pool of donors for leukemia and lymphoma 3Health News:New report explains why physicians are reluctant to share patient data 2
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Central platform with integrated neck. Piston ... utilizing an internal spring to recoil ... Cutting Block fits into precision milled ... blades sized 6.25 - 9.0mm. Designed ...
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
Medicine Products: